Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bortezomib Consolidation After Autologous Stem Cell Transplant in Newly Diagnosed Multiple Myeloma
CTR20132663Phase 3Completed
- Sponsor
- Johnson & Johnson
- Start
- Apr 2015
- Modality
- Reversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of bortezomib in multiple myeloma (MM), sponsored by Johnson & Johnson. Started Apr 2015; status: completed.
02
Drugs
bortezomib
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on CTR20132663.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20132663.